Market Movements - US stock index futures are all up, with Dow futures rising by 0.33%, S&P 500 futures up by 0.31%, and Nasdaq futures increasing by 0.29% [1] - European indices also show positive movement, with Germany's DAX up by 1.22%, UK's FTSE 100 up by 0.11%, France's CAC40 up by 0.74%, and the Euro Stoxx 50 up by 0.59% [2] Oil Prices - WTI crude oil is down by 0.09%, priced at $64.57 per barrel, while Brent crude oil is down by 0.17%, priced at $69.28 per barrel [3] Economic and Market News - David Einhorn of Greenlight Capital predicts that the Federal Reserve will cut interest rates "far more than twice" this year, contrary to market expectations, citing political pressure and upcoming leadership changes at the Fed as catalysts for aggressive rate cuts [4] - John Cito from Apollo Asset Management warns that the software industry is entering a "violent technology cycle," with a significant reset in valuation logic as the market begins to aggressively differentiate between winners and losers [5] - The Federal Reserve is reportedly planning to revoke certain non-public corrective orders issued to banks, signaling a potential easing of regulatory burdens [6] Employment Data - The US non-farm payrolls report for January showed an increase of 130,000 jobs, significantly exceeding the market expectation of 70,000, leading to a delay in rate cut expectations from June to July [7] - Moody's Chief Economist Mark Zandi cautions against overconfidence in the employment data, suggesting that the labor market remains fragile and susceptible to shocks [7] Company-Specific News - Apple (AAPL.US) faces delays in its AI upgrade plan for Siri, with significant features potentially being rolled out in multiple phases rather than all at once [9] - Sanofi (SNY.US) announced a sudden CEO change, with Paul Hudson stepping down amid disappointing R&D results, leading to a drop in stock price by over 6% [10] - Cisco (CSCO.US) reported a 10% year-over-year revenue increase to $15.3 billion, but stock fell over 7% due to concerns over future profit margins amid rising storage chip costs [11] - Applovin (APP.US) reported a 66% revenue increase in Q4, with net profit soaring by 84%, indicating strong performance in the AI and digital advertising space [12] - McDonald's (MCD.US) achieved its fastest revenue growth in over two years, with Q4 sales reaching $7 billion, driven by value meal offerings [13] - Confluent (CFLT.US) exceeded expectations in Q4, with revenue rising by 21% to $314.8 million, marking a strong performance before its acquisition by IBM [14] - Albemarle (ALB.US) reported a Q4 revenue of $1.43 billion but faced a net loss of $455.9 million, leading to a drop in stock price by over 2% [15] - Unilever (UL.US) reported Q4 sales of €12.6 billion, slightly down year-over-year, but expects stable growth in 2026, supported by a €1.5 billion share buyback plan [16]

Market Movements - US stock index futures are all up, with Dow futures rising by 0.33%, S&P 500 futures up by 0.31%, and Nasdaq futures increasing by 0.29% [1] - European indices also show positive movement, with Germany's DAX up by 1.22%, UK's FTSE 100 up by 0.11%, France's CAC40 up by 0.74%, and the Euro Stoxx 50 up by 0.59% [2] Oil Prices - WTI crude oil is down by 0.09%, priced at $64.57 per barrel, while Brent crude oil is down by 0.17%, priced at $69.28 per barrel [3] Economic and Market News - David Einhorn of Greenlight Capital predicts that the Federal Reserve will cut interest rates "far more than two times" this year, contrary to market expectations, citing political pressure and upcoming leadership changes at the Fed as catalysts for aggressive rate cuts [4] - Apollo Global Management warns that the software industry is entering an "extremely violent technology cycle," with a significant reset in valuation logic, emphasizing the need for humility in understanding future market dynamics [5] - The Federal Reserve is signaling a reduction in regulatory burdens for banks, planning to revoke certain non-public corrective orders that were previously issued to improve operations [6] Employment Data - The US non-farm payrolls report for January shows an increase of 130,000 jobs, significantly exceeding the market expectation of 70,000, with the unemployment rate dropping to 4.3% [7] - Moody's chief economist Mark Zandi cautions against overconfidence in the employment data, suggesting that the labor market remains fragile and could easily face shocks [7] Company-Specific News - Apple faces delays in its AI upgrade for Siri, with significant features being split into multiple releases due to testing setbacks [9] - Sanofi announces a leadership change, with CEO Paul Hudson being replaced by Merck executive Paul Garibaldi, following disappointing R&D results [10] - Cisco's Q2 revenue increased by 10% to $15.3 billion, but the stock fell over 7% due to concerns about future profit margins amid rising storage chip costs [11] - Applovin reports a 66% increase in Q4 revenue to $1.66 billion, with net profit soaring by 84%, indicating strong performance in the AI and digital advertising space [12] - McDonald's sees a 9.5% increase in Q4 revenue, driven by value meal offerings, marking the fastest growth in over two years [13] - Confluent's Q4 revenue reaches $314.8 million, with a 21% year-over-year increase, as the company prepares for privatization by IBM [14] - Albemarle reports a Q4 revenue of $1.43 billion but faces a net loss of $455.9 million, leading to a shutdown of key production lines [15] - Unilever's Q4 sales exceed expectations, driven by strong performance in key markets, with a forecast for 2026 sales growth aligning with analyst expectations [16]

Core Insights - Eli Lilly's drugs, Anjoulai and Anjoulai Li (generic name: Mirikizumab), have been approved by the National Medical Products Administration for the treatment of moderate to severe active Crohn's Disease (CD) and Ulcerative Colitis (UC) in adults [1][3] Group 1: Product Approval and Significance - The approval of Anjoulai and Anjoulai Li marks a significant step for Eli Lilly in the inflammatory bowel disease (IBD) treatment field in China, being the first innovative drug approved in this area [1][3] - Anjoulai and Anjoulai Li are IgG4 monoclonal antibodies specifically targeting the IL-23 p19 subunit, selectively inhibiting the IL-23 pathway to modulate immune inflammatory responses [1][3] Group 2: Clinical Data and Efficacy - For Crohn's Disease, the VIVID-1 global phase 3 clinical study showed that 45% of patients in the Anjoulai group achieved clinical response at week 12 and clinical remission at week 52, compared to 20% in the placebo group (p<0.0001) [3] - In the same study, 38% of patients in the Anjoulai group achieved endoscopic response at week 52, compared to 9% in the placebo group (p<0.0001) [3] - For Ulcerative Colitis, the LUCENT global phase 3 clinical study indicated that 64% of patients in the Anjoulai group achieved clinical response after 12 weeks, with 24% achieving clinical remission, significantly outperforming the placebo group [4] Group 3: Safety Profile - In the VIVID-1 study, the most common adverse events reported in the Anjoulai group included COVID-19 infection, anemia, joint pain, headache, and upper respiratory infections [5] - The incidence of serious adverse events in the Anjoulai group was 2.8% after 12 weeks, compared to 5.3% in the placebo group, and serious infection rates were 0.7% versus 0.6% [5] - The discontinuation rate due to adverse events was lower in the Anjoulai group compared to the placebo group during both the induction and maintenance phases [5]

2月12日早间，京新药业（002020）在A股公告，公司已向香港联交所递交上市申请，这家最早专注于中间体与原料药领域，又随着时代发展向创新药转型 的老牌药企，正式踏上了"A+H"两地上市的旅程。据北京商报记者不完全统计，2026年开年仅40余日，已有约30家医药企业递表港交所。 药企扎堆赴港，"创新"成为关键词。上述30家企业中，13家为带有特殊标识"B"的未盈利的创新药、创新医疗器械企业。港交所对未盈利生物科技企业的上 市审核，始终锚定产品的创新性、管线的差异化、临床数据的扎实程度。即便在已盈利的企业阵营中，"创新"同样被屡屡提起。 此外，"A+H"频现也成为此轮药企赴港上市的显著特征。除了京新药业外，还有百普赛斯、迪哲医药、益方生物等A股公司已在年内递表。此外，还有信立 泰、海特生物两股已于年内官宣正在筹划赴港上市。 | 最新发布 申请人 | | | | --- | --- | --- | | 日期 | | | | 12/02/2026 | 仙乐健康科技股份有限公司 | | | | 12/02/2026 整体协调人公告-委任（经修订） 吧 | | | | 29/01/2026 申请版本（第一次呈交）全文档 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][39]. Core Insights - The pharmaceutical sector has shown resilience, outperforming the overall market, with traditional Chinese medicine leading the gains [1][28]. - Roche's oral BTK inhibitor Fenebrutinib has demonstrated non-inferiority to Ocrelizumab in a Phase III trial for primary progressive multiple sclerosis (PPMS), marking a significant advancement in treatment options for this condition [2][11]. - The global market for multiple sclerosis (MS) treatment exceeds $20 billion, with Roche's Ocrevus projected to generate CHF 7 billion in sales by 2025, indicating substantial unmet needs in the PPMS segment [3][25]. Summary by Sections Market Performance - The overall A-share market declined by 1.3%, while the biopharmaceutical sector increased by 0.1%, indicating a stronger performance relative to the market [1][28]. - Specific segments within the biopharmaceutical sector showed varied performance, with traditional Chinese medicine rising by 2.6% and medical services increasing by 1.3% [1][28]. Clinical Data and Drug Development - Roche's Fenebrutinib trial included 985 PPMS patients and achieved its primary endpoint, showing a 12% reduction in disease progression risk compared to Ocrelizumab [2][11]. - The trial results suggest potential benefits for upper limb function, reinforcing the viability of BTK inhibitors in MS treatment [3][25]. Company Earnings Forecast and Investment Recommendations - Key companies in the sector, such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, are rated as "Outperform" with projected earnings growth over the next few years [4][39]. - Mindray Medical is highlighted for its strong R&D and international expansion, while WuXi AppTec is recognized for its comprehensive drug development services [39]. Valuation Metrics - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector stands at 37.31x, compared to the overall A-share market at 21.98x, indicating a premium valuation for the sector [35][36]. - Within the sector, chemical pharmaceuticals and biological products have higher valuations at 45.18x and 46.09x, respectively [35].

证券日报网讯 2月12日，广济药业发布公告称，公司近日收到国家药品监督管理局核准签发的甲钴胺片 的《药品注册证书》，规格为10片/板×2板/盒，注册分类为化学药品4类，批准文号为国药准字 H20263341，用于周围神经病治疗。 （编辑 袁冠琳） ...

Group 1 - The core viewpoint is that Fudan Zhangjiang's stock performance is diverging between its A-share and Hong Kong share listings, with the Hong Kong stock showing significant gains due to favorable market conditions [1] - As of 09:37, Fudan Zhangjiang's Hong Kong stock (01349.HK) was priced at 3.36 HKD, reflecting a 3.38% increase, outperforming its A-share counterpart [1] - The trading activity in the Hong Kong market is robust, with a turnover rate of 0.10% and a transaction amount of approximately 1.04 million HKD [1] Group 2 - The healthcare sector in the Hong Kong stock market is performing well, with the medical-themed sector continuing to rise, and the Hong Kong Stock Connect medical ETF achieving four consecutive gains [2] - This positive sector performance has created a favorable atmosphere for Fudan Zhangjiang's Hong Kong shares [2] Group 3 - The company has made progress in innovative drug development, with its clinical trial application for FZ-P001 sodium, aimed at visualizing malignant lesions in known or suspected lung cancer patients during surgery, receiving acceptance notification [3] - This development may attract market attention towards the company's potential in the field of precision medicine [3]

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report highlights that the recent national procurement has been stable, with limited disruptions, and institutions are increasing their positions in innovative companies, maintaining a positive outlook on undervalued innovative targets [1][4] - The overall market sentiment has improved, driven by significant business development transactions, and the pharmaceutical sector is expected to continue its steady growth in 2026, despite potential short-term volatility [4][5] Summary by Sections Market Performance - The Hang Seng Index rose by 1.3% and the Hang Seng Healthcare Index increased by 5.0%, ranking second among 12 industry indices [4][6] - Sub-sectors such as biopharmaceuticals and CXO both saw a growth of 7.4% [6] Institutional Holdings - Since Q4 2025, the proportion of domestic capital holding pharmaceutical stocks through Hong Kong Stock Connect has slightly decreased, while foreign capital holdings have increased [32] - As of February 10, 2026, domestic holdings were at 22.2%, down 0.2 percentage points, while foreign holdings rose to 39.7%, up 0.9 percentage points [32] Sales Performance - In 2025, China's pharmaceutical market sales decreased by 1% year-on-year, with public hospitals accounting for the largest market share at 10,977 billion RMB, down 2.1% [5] - Retail pharmacy sales reached 5,878 billion RMB, growing by 2.4%, with online pharmacies seeing a significant increase of 13.6% [5] National Procurement - The recent national procurement round had a high selection rate of 93%, with 1,020 products from 1,091 participating companies expected to be implemented by the end of March 2026 [5] - The procurement process has seen increased participation and a diverse range of selected products, ensuring stability in clinical demand [5] Investment Recommendations - The report recommends focusing on innovative drugs, particularly companies like Sanofi and Hengrui Medicine, which have rich catalysts and clear long-term growth logic [4] - It also suggests looking into CXO companies benefiting from high downstream demand and improving financing conditions, such as WuXi AppTec [4]

HRS-5346是恒瑞医药自主研发的口服小分子Lp(a)抑制剂，通过与阻断载脂蛋白(a)[apo(a)]和载脂蛋白B100（ApoB100）之间最初的非共价结合，从而抑制 二硫键和Lp(a)的形成，降低Lp(a)水平。研究结果显示，HRS-5346可有效降低Lp(a)，且安全性良好[3]。 近日，恒瑞医药子公司山东盛迪医药有限公司的HRS-5346用于治疗脂蛋白（a）水平的升高被国家药品监督管理局药品审评中心纳入突破性治疗品种名 单。 脂蛋白(a)[Lp(a)]水平升高是全球最普遍的单基因脂质疾病，是脂蛋白紊乱的典型表现之一。中国成年人的Lp(a)水平＞30mg/dL和50mg/dL的患病率分别为 18.67%和8.41%[1]。Lp(a)升高已被证实为动脉粥样硬化性心血管疾病（ASCVD）包括冠心病、缺血性脑卒中、外围血管疾病及钙化性主动脉瓣狭窄等疾 病的独立危险因素[2]。靶向Lp(a)的降脂疗法是心血管疾病防治的潜在新方向之一，但目前尚无针对降低Lp(a)适应症的治疗药物，该疗法仍处于临床研究 阶段。 近日，恒瑞医药子公司山东盛迪医药有限公司的HRS-5346用于治疗脂蛋白（a）水平的升高被国家药品监督 ...

Group 1 - The company emphasizes the importance of innovative drug research and talent development, indicating a strategic focus on these areas [2] - Multiple original first-class drugs are currently in orderly progress towards clinical trial stages, showcasing the company's commitment to innovation [2] - The company plans to continuously optimize its talent recruitment mechanism and allocate professional resources based on research and development progress [2]